Among clinically validated strategies for addressing CRS, IL-6R blockade with tocilizumab and IL-1R inhibition with anakinra have demonstrated robust mitigation of neurotoxicity and CRS in patients, marking a clear translational success [451]. The gene discussed is IL6R; the disease is congenital rubella syndrome.